© Reuters. Pharmamar rises 0.11% after drug approval in CanadaUpdate EC4106 with transaction closing details
Madrid, Sept. 30 (.) Treatment of lung cancer.
The pharmaceutical company, which had risen more than 2% at some point in the session, led the improvement of the key indicator of the national market, ending today at eight euros higher at 74.48 euros per share.
During the year of accumulation, its shares are revalued at 5.58%.
Fusion Media No one associated with Fusion Media will be liable for any loss or damage as a result of relying on information on the Website, including buying / selling data, quotes, charts and signals. Please be fully informed about the risks and costs associated with financial market trading, which is one of the potentially risky investment forms.

“Devoted music specialist. Student. Zombie trailblazer. Internetaholic. Food geek.”

More Stories
8 Benefits of New or Replacement Windows for Your Toronto Home
Top 9 Tips on How Not to Spend Too Much at the Store
Travel Essentials for a Road Trip